Search Results for “EU” – Page 396 – media

Verastem’s Duvelisib Succeeds in Late-Stage Blood Cancer Study

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today reported positive top-line results from the Phase 3 DUO study evaluating the efficacy and safety of duvelisib, a first in class oral dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma, in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
- Source: Spjnews
- 745
- September 8, 2017
cancer Clinical Trials CLL inhibitor SLL
Stent Tek Closes Series A Investment Round for its ePATH AVF Device, Aiming to Improve Vascular Access for Haemodialysis

Stent Tek, a medical device company that is developing a minimally invasive catheter system for dialysis patients, announced today it has successfully closed a Series A funding round with investments from two institutional investors.
- Source: prnewswire
- 587
- September 8, 2017
catheter invasive Market Views Series
National Hospitalist Conference

The National Hospitalist Conference will be held in Santa Fe, New Mexico at the Eldorado Hotel & Spa on September 8-10, 2017. The National Hospitalist Conference is designed to provide physicians, physician assistants, and nurse practitioners with information and skills to improve the care of their hospitalized patients.
- Source: medical-events
- 643
- September 8, 2017
Exhibitions & Activities hospitalized
Sanofi wins tentative FDA nod for Admelog insulin lispro injection

Sanofi announced that the U.S. Food and Drug Administration (FDA) granted tentative approval for Admelog® (insulin lispro injection) 100 Units/mL, a rapid-acting human insulin analog. Admelog is indicated to improve glycemic control in adults and children with diabetes mellitus.
- Source: yahoo
- 740
- September 7, 2017
Company Insight diabetes FDA insulin New Approvals
Merck KGaA Plans Consumer Healthcare Sale After Strategic Review

Germany's Merck KGaA is looking to sell its $1 billion consumer healthcare unit after a group-wide strategic review.
- Source: thestreet
- 601
- September 7, 2017
Company Insight healthcare Market Views Merck
The World’s Largest and Most Powerful X-Ray Laser Just Went Online

The European XFEL is now online. Built to be the world's largest facility to house the most powerful x-ray lasers that can be produced, the XFEL would contribute to a better understanding of molecular and chemical process by imaging particles.
- Source: Futurism
- 542
- September 7, 2017
molecular x-ray XFEL
Ddu to Attend Expo Medical Expanding the South American Medical Trade Market

The 15th International Show for Products, Equipment and Services for the Healthcare Sector(Expo Medical) will be held at Centro Costa Salguero, Buenos Aires, Argentina from September 27 to September 29, 2017. As the leading global pharmaceutical and medical device B2B online platform, Ddu is going to attend the exhibition along with the products of high priority members and commits itself to the development of the South American medical trade market.
- Source: Ddu
- 821
- September 6, 2017
Exhibitions & Activities Expo Medical medical device pharmaceutical
FDA holds trials of Cellectis’ cell therapy after patient death

US regulators have placed on hold studies of French drugmaker Cellectis’ CAR-T therapy following a patient fatality.
- Source: news.open-medical
- 581
- September 6, 2017
BPDCN CAR–T Clinical Trials Company Insight CRS
Takeda and Noile-Immune Biotech Collaborate to Advance Next Generation CAR-T Cell Therapy Effective for Solid Tumors

A collaboration to develop next generation chimeric antigen receptor T cell therapy (CAR-T) (RELATED: Kite begins EU trial of CAR–T therapy) was announced by Takeda Pharmaceutical Company Limited (TSE: 4502) and Noile-Immune Biotech Inc..
- Source: Takeda
- 883
- September 6, 2017
antigen CAR–T Market Views receptor therapy
Amgen Ventures Invests in GNS Healthcare to Advance Applications of its REFS™ Causal Machine Learning and Simulation AI Platforms

GNS Healthcare (GNS), a leading precision medicine company, today announced that it has raised an additional $6 million in equity from Amgen Ventures with participation from existing investor Alexandria Real Estate Equities. The funds will be used to further develop the company's REFS™ causal machine learning and simulation platform and solutions across drug discovery & development, value-based drug solutions, care management, and health system business optimization. With this investment, Amgen Ventures joins other leading biopharma companies Celgene and Zambon Pharmaceuticals, leading health plans Regence Blue Cross Blue Shield (Cambia Health Solutions), and Horizon Blue Cross of NJ and provider Heritage Provider Network, in addition to Mitsui, GHO Capital, and Fort Rock Capital as shareholders of GNS.
- Source: Prnewswire
- 571
- September 5, 2017
Market Views platform solution

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.